Table A2.
Changes in characteristics at week 16, after 12 weeks of treatment following randomisation to metronidazole/inulin, placebo/inulin or placebo/placebo.
| Clinical Characteristics | Group MI: Metronidazole-Inulin (n = 19) |
Group PI: Placebo-Inulin (n = 19) |
Group PP: Placebo-Placebo (n = 18) |
p-Value Group MI vs. PP | p-Value Group PI vs. PP |
|---|---|---|---|---|---|
| Body mass index (kg/m2) | 0.10 (1.20) | 0.12 (1.80) | 0.21 (1.36) | 0.792 | 0.859 |
| Weight (kg) | 0.35 (3.38) | 0.29 (5.02) | 0.47 (4.10) | 0.922 | 0.910 |
| Waist:hip ratio | −0.00 (0.04) | −0.01 (0.04) | −0.00 (0.06) | 0.893 | 0.604 |
| Blood pressure (mm Hg) | |||||
| Systolic Diastolic |
3.4 (11.3) −1.4 (10.2) |
2.2 (16.7) 0.4 (12.0) |
−7.2 (18.4) 0.5 (13.8) |
0.043 0.641 |
0.117 0.981 |
| ALT (U/L) | −19.6 (25.5) | −2.2 (16.7) | −0.2 (24.5) | 0.026 | 0.856 |
| AST (U/L) | −14 (−32, −7) | −3 (−22, 2) | −4 (−9, 5) | 0.006 | 0.849 |
| GGT (U/L) | 13 (−2, 29) | 26 (−1, 91) | 17 (8, 62) | 0.274 | 0.693 |
| Bilirubin (µmol/L) | −1 (−3, 1) | −2 (−3, 0) | 1 (−2, 2) | 0.115 | 0.033 |
| Albumin (g/L) | 0.13 (1.81) | −1.17 (2.46) | −1.14 (2.57) | 0.131 | 0.979 |
| Ferritin (µg/L) | −56.3 (60.1) | −27.6 (63.5) | −1.3 (72.7) | 0.031 | 0.291 |
| Cholesterol (mmol/L) | |||||
| Total HDL LDL |
1.09 (1.10) 0.16 (0.15) 2.28 (5.56) |
1.32 (1.13) 0.20 (0.24) 0.83 (0.77) |
0.91 (0.57) 0.13 (0.17) 0.55 (0.49) |
0.560 0.638 0.181 |
0.208 0.344 0.246 |
| Triglycerides (mmol/L) | 0.52 (0.32) | 0.50 (0.79) | 0.56 (0.64) | 0.831 | 0.814 |
| Fasting glucose (mmol/L) | 0.39 (1.32) | 0.18 (0.70) | 1.14 (2.05) | 0.228 | 0.077 |
| HbA1c (mmol/mol) | 1.94 (4.25) | 0 (5.79) | 2.06 (6.02) | 0.947 | 0.316 |
| CRP (mg/L) | 0.0 (−1.0, 0.75) | 1.0 (0.0, 1.5) | 0.0 (0.0, 1.0) | 0.884 | 0.235 |
| Fibroscan CAP (dB/m) | 14.5 (65.6) | 22.4 (71.6) | 10.8 (42.6) | 0.859 | 0.605 |
Data are mean (SD) or median (Q1, Q3).